Monopar Therapeutics (MNPR): Submission of Matters to a Vote of Security Holders
Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. mnpr20260622_8k.htm false 0001645469 0001645469 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo
How this was made
The 30-second read
Why it matters
The company’s shareholders elected six directors, approved advisory NEO compensation, approved the 2026 Stock Incentive Plan, and ratified BPM LLP as independent auditor for 2026.
Market read
This is primarily a governance/equity-plan confirmation filing; it does not introduce new clinical, regulatory, or financial guidance in the provided text.
What to watch
Because the vote is advisory for NEO compensation and the filing lacks plan size/terms in the excerpt, the market may not price it meaningfully without additional details from the proxy/plan document.
Background
The filing is an SEC Form 8-K Item 5.07 reporting matters submitted to a vote of security holders at Monopar Therapeutics’ June 22, 2026 annual meeting.
Ticker impact
Monopar Therapeutics reported 2026 annual meeting voting results, including director elections, advisory NEO compensation approval, and a 2026 stock incentive plan.
Limited near-term impact; any reaction is likely muted unless investors focus on dilution implications of the newly approved incentive plan.
The 8-K discloses standard proxy vote tallies (directors, advisory comp, stock incentive plan, auditor ratification) without new business milestones or financial targets.
Market effects
Minimal; governance and equity-plan approval is company-specific and not a sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
The stock incentive plan approval could still matter if investors interpret it as signaling higher future hiring/option grants, potentially affecting dilution expectations.
Key entities
- public_companyMonopar Therapeutics Inc.
Nasdaq-listed company that held its annual meeting and reported shareholder vote results via Form 8-K.
- accounting_firmBPM LLP
Independent registered public accounting firm ratified for the year ending December 31, 2026.
